Coakley, M. orcid.org/0000-0003-2658-7789, Villacampa, G. orcid.org/0000-0003-4868-6585, Sritharan, P. orcid.org/0009-0004-9733-3596 et al. (21 more authors) (2024) Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer. Clinical Cancer Research, 30 (4). pp. 895-903. ISSN 1078-0432
Abstract
Purpose: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk of relapse, yet the optimal assay for ctDNA detection is unknown.
Experimental Design: The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays for ctDNA molecular residual disease (MRD) detection in early-stage triple-negative breast cancer. We compared tumor-informed dPCR assays with tumor-informed personalized multimutation sequencing assays in 141 patients from cTRAK-TN.
Results: MRD was first detected by personalized sequencing in 47.9% of patients, 0% first detected by dPCR, and 52.1% with both assays simultaneously (P < 0.001; Fisher exact test). The median lead time from ctDNA detection to relapse was 6.1 months with personalized sequencing and 3.9 months with dPCR (P = 0.004, mixed-effects Cox model). Detection of MRD at the first time point was associated with a shorter time to relapse compared with detection at subsequent time points (median lead time 4.2 vs. 7.1 months; P = 0.02).
Conclusions: Personalized multimutation sequencing assays have potential clinically important improvements in clinical outcome in the early detection of MRD.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | ©2023 The Authors; Published by the American Association for Cancer Research. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
Keywords: | Humans; Circulating Tumor DNA; Triple Negative Breast Neoplasms; Neoplasm Recurrence, Local; Recurrence; Biomarkers, Tumor; Neoplasm, Residual |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 22 Mar 2024 12:14 |
Last Modified: | 22 Mar 2024 12:14 |
Published Version: | http://dx.doi.org/10.1158/1078-0432.ccr-23-2326 |
Status: | Published |
Publisher: | American Association for Cancer Research (AACR) |
Refereed: | Yes |
Identification Number: | 10.1158/1078-0432.ccr-23-2326 |
Related URLs: | |
Sustainable Development Goals: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:210765 |